| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company...
Repare Therapeutics (NASDAQ:RPTX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of...
Under the terms of the out-licensing agreement, Repare will receive upfront and near-term payments totaling $4 million, as well...
On April 11th, 2025, Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable ...